Product Description
Mechanisms of Action: D2 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Subcutaneous,Transdermal
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Chile | Colombia | Dominican Republic | Egypt | France | Germany | Ireland | Italy | Mexico | New Zealand | Pakistan | Peru | Portugal | Taiwan | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Axxonis Pharma AG
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Parkinson's Disease|Restless Legs Syndrome|Psychomotor Agitation
Phase 2: Parkinson's Disease|Hypertension, Pulmonary
Phase 1: Cocaine-Related Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| Lis-Safe | P2 |
Terminated |
Hypertension, Pulmonary |
2014-08-19 |
2022-03-13 |
Treatments |
|
| CALIPSO | P3 |
Completed |
Parkinson's Disease |
2009-10-02 |
2022-03-12 |
Treatments |
|
| TULEP 1 | P3 |
Active, not recruiting |
Parkinson's Disease |
2008-09-20 |
2025-05-30 |
Treatments |
|
| Tulir03/01 | P3 |
Active, not recruiting |
Restless Legs Syndrome |
2007-09-08 |
2022-03-12 |
Treatments |
|
| 2004-001589-42 | P3 |
Active, not recruiting |
Restless Legs Syndrome |
2006-08-25 |
2022-03-12 |
Treatments |
|
| 04-N-0258 | P2 |
Completed |
Parkinson's Disease |
None |
2019-03-21 |
Treatments |
|
| Lisuride | P1 |
Unknown status |
Cocaine-Related Disorders |
None |
2019-03-21 |
Treatments |
|
| CALIPSO | P3 |
Completed |
Parkinson's Disease |
None |
2019-03-21 |
Treatments |
|
| Transdermal Lisuride | P3 |
Completed |
Restless Legs Syndrome|Psychomotor Agitation |
None |
2019-03-21 |
Treatments |